secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001213900-24-113159
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025
--------------------------------------------------------------------------------

- Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.
- FDA approved LYMPHIR for relapsed/refractory CTCL; commercial launch planned H1 2025.
- Pre-commercial activities: J-code application, NCCN inclusion, CSO recruitment, inventory built.
- R&D $4.9M, G&A $8.1M, stock-based comp $7.5M vs $4.2M, $5.9M, $2.0M YoY.
- Phase I combo with pembrolizumab showed 27% ORR, 33% CBR, median PFS 57 weeks in gynecological tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/0001213900-24-113159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/ea0226165-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-113159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer